EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Pembrolizumab-Associated Severe Radiation Recall Dermatitis in a Patient with Metastatic Head and Neck Carcinoma: A Case Report

Madalena Silveira Machado, André Abrunhosa-Branquinho, Sara Magno, Pedro Freitas, Margarida Rafael, Madalena P Santos, Isabel Sargento

Case Reports in Oncology · 06.04.2026 · 19 (1) · 695-703

DOI: 10.1159/000551844 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 06.04.2026. Verfasst von Madalena Silveira Machado und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Radiation recall dermatitis is defined as an acute skin reaction confined to a previously irradiated area that occurs following the administration of systemic therapy. Pembrolizumab is a standard of care for metastatic or recurrent head and neck squamous cell carcinoma, particularly in patients previously treated with radiotherapy. Its use is expanding into resectable settings, both in combination with and following radiotherapy. Case Presentation: We present the case of a 65-year-old man diagnosed with p16 negative stage IVB squamous cell carcinoma of the oropharynx treated with definitive chemoradiotherapy. Five months later, disease progression was observed. He received a first cycle of pembrolizumab, 7 months and 20 days after his last radiation dose. Ten days later, he developed burn-like pain, erythema and edema of the left side of the face and neck, progressing to epidermal detachment, with a positive Nikolsky sign involving the entire neck and left supraclavicular area, along with grade 4 mucositis with purulent exudate. Skin biopsy findings were consistent with drug hypersensitivity and chronic radiation changes. No improvement was observed with antibiotic therapy, and stabilization was achieved on the second day of 30 mg of prednisolone. Unfortunately, the patient experienced disease progression after discharge from hospitalization.

Conclusion

This case further contributes to the description of a dermatosis that remains insufficiently understood and whose incidence may rise with the broader use of immunoradiotherapy.

Schlagwörter

Stichwörter der Autor:innen

DermatitisImmune checkpoint inhibitorMucositisPembrolizumabRadiation recall

Autor:innen und Institutionen

  • Department of Medical Oncology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
  • Department of Radiation Oncology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
  • Department of Dermatology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.

Zitieren

APA

Machado, M. S., Abrunhosa-Branquinho, A., Magno, S., Freitas, P., Rafael, M., Santos, M. P., & Sargento, I. (2026). Pembrolizumab-Associated Severe Radiation Recall Dermatitis in a Patient with Metastatic Head and Neck Carcinoma: A Case Report. Case Reports in Oncology, 19(1), 695-703. https://doi.org/10.1159/000551844

Vancouver

Machado MS, Abrunhosa-Branquinho A, Magno S, Freitas P, Rafael M, Santos MP, et al. Pembrolizumab-Associated Severe Radiation Recall Dermatitis in a Patient with Metastatic Head and Neck Carcinoma: A Case Report. Case Reports in Oncology. 2026;19(1):695-703. doi:10.1159/000551844

BibTeX
@article{Machado2026,
  author = {Machado, Madalena Silveira and Abrunhosa-Branquinho, André and Magno, Sara and Freitas, Pedro and Rafael, Margarida and Santos, Madalena P and Sargento, Isabel},
  title = {Pembrolizumab-Associated Severe Radiation Recall Dermatitis in a Patient with Metastatic Head and Neck Carcinoma: A Case Report},
  journal = {Case Reports in Oncology},
  year = {2026},
  volume = {19},
  number = {1},
  pages = {695--703},
  doi = {10.1159/000551844}
}
Kostenlos starten →